Actively Recruiting
Phase 2 Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy IMPRINT for Adults With Thymic Cancer That Has Spread to the Lung Lining
Led by Memorial Sloan Kettering Cancer Center · Updated on 2026-05-06
36
Participants Needed
7
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating hemithoracic intensity-modulated pleural radiation therapy IMPRINT to determine if it is a safe treatment option with minimal side effects for people with thymic malignancies that have spread to the lining of the lungs and chest. The study also aims to assess whether this radiation therapy is effective against cancer in these patients. This is a Phase II clinical trial sponsored by Memorial Sloan Kettering Cancer Center. Participants will receive radiation therapy over about 6 weeks, with a total dose of 50.4 Gy given in 28 sessions. There is an option for a higher dose to areas of visible remaining cancer while protecting normal tissues. This treatment targets the affected hemithoracic pleura, the lining of one side of the chest. During the study, participants will be monitored for side effects such as radiation pneumonitis over two years. Researchers will also measure progression-free survival at 12 months to see how well the cancer is controlled. Participants will have regular assessments including lung function tests and kidney function evaluations to ensure safety, with study participation lasting for at least two years of follow-up.
CONDITIONS
Brief Title
A Study of Intensity-Modulated Pleural Radiation Therapy (IMPRINT) in People With Thymic Cancer That Has Spread to the Lining of the Lungs and Chest
Research Team
C
Charles Simone, MD
A
Andrew Pagano, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
